News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RedHill Biopharma Ltd. is Preparing for an Advanced Clinical Trial with RHB-102, a Drug for the Prevention of Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy and Radiotherapy



11/3/2011 9:39:20 AM

TEL AVIV, Israel--(BUSINESS WIRE)--RedHill Biopharma Ltd. (TASE: RDHL), an emerging Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical-stage new formulations and combinations of existing drugs, reported an engagement with Algorithme Pharma, Inc. a Canadian CRO (Clinical Research Organization), for the execution of an advanced clinical trial with RHB-102, a drug designated to prevent chemotherapy and radiotherapy induced nausea and vomiting.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES